Quest Diagnostics (DGX) vs Natera (NTRA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Natera (NTRA) has outperformed Quest Diagnostics (DGX) over the past year, gaining 127.1% versus a gain of 27.6%. Over five years, NTRA leads with a +252.8% price change compared with +62.0% for DGX. Natera is the larger company by market cap ($56.33 billion vs $25.48 billion), about 2.2 times the size.
Quest Diagnostics pays a dividend yielding 1.44%, while Natera does not currently pay one. Quest Diagnostics converts more of its revenue into profit, with a net margin of 9.0% versus -9.0%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | DGX | NTRA |
|---|---|---|
| Share price | $230.81 | $390.79 |
| Market cap | $25.48B | $56.33B |
| 1-day change | +1.65% | -1.21% |
| YTD return | +33.01% | +70.58% |
| 1-year return | +27.60% | +127.08% |
| 5-year return | +61.97% | +252.79% |
| P/E ratio (TTM) | 24.50 | — |
| Forward P/E | 19.18 | — |
| EPS (TTM) | $9.42 | $-1.35 |
| Dividend yield | 1.44% | 0.00% |
| Annual dividend | $3.32 | $0.00 |
| Revenue (latest FY) | $11.04B | $2.31B |
| Revenue growth (YoY) | +11.78% | +35.90% |
| Net income (latest FY) | $992.00M | $-208.16M |
| Gross margin | 33.21% | — |
| Operating margin | 14.10% | -13.44% |
| Net margin | 8.99% | -9.03% |
| 52-week high | $248.84 | $437.41 |
| 52-week low | $171.18 | $167.99 |
| Distance from 52-week high | -7.25% | -10.66% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +7.48% | -3.42% |
| Average volume | 1.04M | 1.45M |
| Shares outstanding | 110.37M | 144.14M |
| Employees | 46,000 | 6,135 |
| Sector | Health Care | Health Care |
| Industry | Medical Specialities | Medical Specialities |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Natera is about 2.2 times larger than Quest Diagnostics by market value ($56.33B vs $25.48B).
- NTRA has outperformed DGX by 99.5 percentage points over the past year.
- Quest Diagnostics offers a meaningfully higher dividend yield (1.44% vs 0.00%).
- Quest Diagnostics is more profitable, keeping 9.0 cents of every revenue dollar as net income versus -9.0 cents for Natera.
- Natera grew revenue faster in its latest fiscal year (+35.90% vs +11.78%).
About Quest Diagnostics
DGX stock →Quest Diagnostics Incorporated provides diagnostic testing and services in the United States. The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services.
Health Care · Medical Specialities · 46,000 employees
About Natera
NTRA stock →Natera, Inc., a diagnostics company, engages in the development and commercialization of molecular testing services worldwide. It offers Signatera, a personalized ctDNA blood test for MRD assessment, early recurrence monitoring, and evaluation of treatment response in patients previously diagnosed with cancer; Latitude, a blood-based MRD test for colorectal cancer; Altera, a tissue based comprehensive genomic profiling test; and Empower, a hereditary cancer screening test.
Health Care · Medical Specialities · 6,135 employees
DGX vs NTRA FAQ
Which is bigger, Quest Diagnostics or Natera?
Natera (NTRA) is larger, with a market capitalization of $56.33B compared with $25.48B for Quest Diagnostics (DGX).
Which stock has performed better over the past year, DGX or NTRA?
NTRA returned +127.08% over the past 12 months, compared with +27.60% for DGX (price return, excluding dividends). Past performance does not predict future results.
Which pays a higher dividend, Quest Diagnostics or Natera?
Quest Diagnostics pays a dividend yielding 1.44%, while Natera does not currently pay a regular dividend.
Are Quest Diagnostics and Natera in the same industry?
Yes. Both are classified in the Medical Specialities industry within the Health Care sector.